{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["33(24)"],"submitter":["Ciprotti M"],"pubmed_abstract":["<h4>Purpose</h4>CS-1008 (tigatuzumab) is a humanized, monoclonal immunoglobulin G1 (IgG1) agonistic antibody to human death receptor 5. The purpose of this study was to investigate the impact of CS-1008 dose on the biodistribution, quantitative tumor uptake, and antitumor response in patients with metastatic colorectal cancer (mCRC).<h4>Patients and methods</h4>Patients with mCRC who had received at least one course of chemotherapy were assigned to one of five dosage cohorts and infused with a weekly dose of CS-1008. Day 1 and day 36 doses were trace-labeled with indium-111 ((111)In), followed by whole-body planar and regional single-photon emission computed tomography (SPECT) imaging at several time points over the course of 10 days.<h4>Results</h4>Nineteen patients were enrolled. (111)In"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pagination":["2609-16"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4881374"],"repository":["biostudies-literature"],"pubmed_title":["Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer."],"pmcid":["PMC4881374"],"pubmed_authors":["Matsumura M","Greenberg J","Scott AM","Chong G","Beckman RA","Scott FE","Hopkins W","Lee FT","Venhaus R","Kotsuma M","McKee DC","Gong SJ","Ciprotti M","O'Keefe GJ","Chappell B","Lee ST","Tebbutt NC","Brechbiel MW","Tse AN","Watanabe R","Gan HK","Jansen M"],"additional_accession":[]},"is_claimable":false,"name":"Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.","description":"<h4>Purpose</h4>CS-1008 (tigatuzumab) is a humanized, monoclonal immunoglobulin G1 (IgG1) agonistic antibody to human death receptor 5. The purpose of this study was to investigate the impact of CS-1008 dose on the biodistribution, quantitative tumor uptake, and antitumor response in patients with metastatic colorectal cancer (mCRC).<h4>Patients and methods</h4>Patients with mCRC who had received at least one course of chemotherapy were assigned to one of five dosage cohorts and infused with a weekly dose of CS-1008. Day 1 and day 36 doses were trace-labeled with indium-111 ((111)In), followed by whole-body planar and regional single-photon emission computed tomography (SPECT) imaging at several time points over the course of 10 days.<h4>Results</h4>Nineteen patients were enrolled. (111)In","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Aug","modification":"2025-06-01T12:01:41.577Z","creation":"2019-03-27T02:14:35Z"},"accession":"S-EPMC4881374","cross_references":{"pubmed":["26124477"],"doi":["10.1200/JCO.2014.60.4256","10.1200/jco.2014.60.4256"]}}